Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
331
mi
from 43215
Nashville, TN
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated:  12/31/1969
University of Washington Autism Center
2006
mi
from 43215
Seattle, WA
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated: 12/31/1969
University of Washington Autism Center
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated:  12/31/1969
Jackson Memorial Hospital
992
mi
from 43215
Miami, FL
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated: 12/31/1969
Jackson Memorial Hospital
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospital
993
mi
from 43215
Miami, FL
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospital
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
Status: Enrolling
Updated:  12/31/1969
University of Florida Health Science Center
714
mi
from 43215
Gainesville, FL
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
Status: Enrolling
Updated: 12/31/1969
University of Florida Health Science Center
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
Stanford University
2100
mi
from 43215
Stanford, CA
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
Stanford University
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
Massachusetts Eye and Ear
641
mi
from 43215
Boston, MA
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
Massachusetts Eye and Ear
641
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
1972
mi
from 43215
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
2102
mi
from 43215
Palo Alto, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
2102
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
545
mi
from 43215
Farmington, CT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
545
mi
from 43215
Farmington, CT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
164
mi
from 43215
Ann Arbor, MI
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Rutgers Robert Wood Johnson Medical School
455
mi
from 43215
New Brunswick, NJ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Rutgers Robert Wood Johnson Medical School
455
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina Medical Center
524
mi
from 43215
Charleston, SC
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina Medical Center
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Texas Medical Center
mi
from 43215
Houston, TX
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Texas Medical Center
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Utah Health Care
1513
mi
from 43215
Salt Lake City, UT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Utah Health Care
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Liverpool Hospital
9473
mi
from 43215
Liverpool,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Liverpool Hospital
9473
mi
from 43215
Liverpool,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
328
mi
from 43215
Washington,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Ronald Reagan UCLA Medical Center
1982
mi
from 43215
Los Angeles, CA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Ronald Reagan UCLA Medical Center
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of California, Davis Medical Center
2043
mi
from 43215
Sacramento, CA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of California, Davis Medical Center
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of Iowa Children's Hospital
460
mi
from 43215
Iowa City, IA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of Iowa Children's Hospital
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Kennedy Krieger Institute
345
mi
from 43215
Baltimore, MD
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Kennedy Krieger Institute
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
354
mi
from 43215
Rochester, NY
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
2005
mi
from 43215
Seattle, WA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
St. Louis Children's Hospital
397
mi
from 43215
Saint Louis, MO
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
St. Louis Children's Hospital
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With
Status: Enrolling
Updated:  12/31/1969
University of Utah School of Medicine
1511
mi
from 43215
Salt Lake City, UT
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With
Status: Enrolling
Updated: 12/31/1969
University of Utah School of Medicine
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Atomoxetine in Veterans With Comorbid ADHD/PTSD
Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study
Status: Enrolling
Updated:  12/31/1969
Ralph H. Johnson VA Medical Center, Charleston, SC
525
mi
from 43215
Charleston, SC
Atomoxetine in Veterans With Comorbid ADHD/PTSD
Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study
Status: Enrolling
Updated: 12/31/1969
Ralph H. Johnson VA Medical Center, Charleston, SC
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Division of Research Kaiser Permanente
2098
mi
from 43215
Oakland, CA
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Division of Research Kaiser Permanente
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined Repetitive Transcranial Magnetic Stimulation and Brain-Computer Interface Training
Status: Enrolling
Updated:  12/31/1969
Clinical and Translational Science Institute
624
mi
from 43215
Minneapolis, MN
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined Repetitive Transcranial Magnetic Stimulation and Brain-Computer Interface Training
Status: Enrolling
Updated: 12/31/1969
Clinical and Translational Science Institute
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12284
530
mi
from 43215
Tuscaloosa, AL
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12284
530
mi
from 43215
Tuscaloosa, AL
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
1960
mi
from 43215
Anaheim, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
1960
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
1960
mi
from 43215
Anaheim, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
1960
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10738
1970
mi
from 43215
Glendale, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10738
1970
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 004
1960
mi
from 43215
Irvine, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 004
1960
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 004
1960
mi
from 43215
Irvine, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 004
1960
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 176
1920
mi
from 43215
Loma Linda, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 176
1920
mi
from 43215
Loma Linda, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1972
mi
from 43215
Los Angeles, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1972
mi
from 43215
Los Angeles, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 174
1967
mi
from 43215
Norwalk, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 174
1967
mi
from 43215
Norwalk, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
1949
mi
from 43215
Oceanside, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
1949
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
1949
mi
from 43215
Oceanside, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
1949
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10140
1958
mi
from 43215
Orange, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10140
1958
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1951
mi
from 43215
San Diego, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 169
1968
mi
from 43215
San Rafael, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 169
1968
mi
from 43215
San Rafael, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 038
1163
mi
from 43215
Englewood, CO
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 038
1163
mi
from 43215
Englewood, CO
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12287
327
mi
from 43215
Washington,
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12287
327
mi
from 43215
Washington,
Click here to add this to my saved trials